Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 294-298

  Sun, Jong Mu ^a   Ahn, Myung Ju ^a   Choi, Yoon La ^a   Ahn, Jin Seok ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Afatinib; Epidermal growth factor receptor; Resistance; T790M; Tyrosine kinase inhibitor

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TISSUE SECTION;

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; RESISTANCE; T790M; TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CODON; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TREATMENT OUTCOME;

EID: 84887016132     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.023     Document Type: Article

References (32)

1. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
2. Sun J.M., Rampal S., Lee G., Lee J., Choi Y.L., Parasuraman B., et al. Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer. Lung Cancer 2013, 80:191-196.
3. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104:20932-20937.
4. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3. 75ra26.
5. Chmielecki J., Foo J., Somwar R., Regales L., Vivanco I., Shen R., et al. EGFR T790M decreases growth potential of lung tumor cells with drug-sensitive EGFR mutant alleles in the absence of drug selection. AACR 100th Annual Meeting 2009, (abstract 4217).
6. Arcila M.E., Oxnard G.R., Nafa K., Riely G.J., Solomon S.B., Zakowski M.F., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011, 17:1169-1180.
7. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
8. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
9. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19:2240-2247.
10. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008, 105:2070-2075.
11. Hata A., Katakami N., Yoshioka H., Takeshita J., Tanaka K., Nanjo S., et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: comparison between T790M mutation-positive and -negative populations. J Clin Oncol 2012, Suppl (30). (abstr 7528).
12. Oxnard G.R., Arcila M.E., Sima C.S., Riely G.J., Chmielecki J., Kris M.G., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.
13. Uramoto H., Yano S., Tanaka F. T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI. Lung Cancer 2012, 76:129-130.
14. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
15. Rosell R., Molina M.A., Costa C., Simonetti S., Gimenez-Capitan A., Bertran-Alamillo J., et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011, 17:1160-1168.
16. Su K.Y., Chen H.Y., Li K.C., Kuo M.L., Yang J.C., Chan W.K., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012, 30:433-440.
17. Kim Y., Ko J., Cui Z., Abolhoda A., Ahn J.S., Ou S.H., et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther 2012, 11:784-791.
18. Sequist L.V., Besse B., Lynch T.J., Miller V.A., Wong K.K., Gitlitz B., et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:3076-3083.
19. Choi Y.L., Sun J.M., Cho J., Rampal S., Han J., Parasuraman B., et al. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS ONE 2013, 8:e56011.
20. Ma C., Wei S., Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011, 3:10-18.
21. Oxnard G.R., Arcila M.E., Chmielecki J., Ladanyi M., Miller V.A., Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011, 17:5530-5537.
22. Mulloy R., Ferrand A., Kim Y., Sordella R., Bell D.W., Haber D.A., et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007, 67:2325-2330.
23. Vikis H., Sato M., James M., Wang D., Wang Y., Wang M., et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 2007, 67:4665-4670.
24. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67:11924-11932.
25. Li D., Ambrogio L., Shimamura T., Kubo S., Takahashi M., Chirieac L.R., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
26. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13:528-538.
27. Godin-Heymann N., Ulkus L., Brannigan B.W., McDermott U., Lamb J., Maheswaran S., et al. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008, 7:874-879.
28. Walter A.O., Tjin R., Haringsma H., Lin K., Dubrovskiy A., Lee K., et al. CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations. Mol Cancer Ther 2011, 10(Suppl 1):C189.
29. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
30. National Institutes of Health. Study to evaluate safety, pharmacokinetics, and preliminary efficacy of CO-1686 in previously treated mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). Available from: http://www.clinicaltrials.gov/show/NCT01526928, accessed 13.04.2013.
31. National Institutes of Health. Clinical Trials Registry. AZD9291 First time in patients ascending dose study. Available from: http://www.clinicaltrials.gov/show/NCT01802632, accessed 21.06.2013.
32. Sequist L.V., Soria J.C., Gadgeel S.M., Wakelee H., Camidge D.R., Varga A., et al. First-in-human evaluation of CO-1686, an irreversible, selective and potent tyrosine kinase inhibitor of EGFR T790M. J Clin Oncol 2013, Suppl (30). (abstract 2524).